Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases

Journal of Controlled Release

Volumn 235, Issue , 2016, Pages 34-47

  Saraiva, Cláudia ^a   Praça, Catarina ^b,c,d,e   Ferreira, Raquel ^a   Santos, Tiago ^a   Ferreira, Lino ^b,c,d   Bernardino, Liliana ^a  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b Biocant Center of Innovation in Biotechnology   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e UNIVERSITÉ D'ARTOIS   (France)

Author keywords

Alzheimer's disease; Blood brain barrier; Brain repair; Nanoparticles; Parkinson's disease; Stroke

Indexed keywords

BLOOD; CONTROLLED DRUG DELIVERY; MOLECULES; NANOPARTICLES; NEURODEGENERATIVE DISEASES; PATHOLOGY;

ALZHEIMER'S DISEASE; BLOOD-BRAIN BARRIER; BRAIN DRUG DELIVERIES; MULTICELLULAR STRUCTURE; PARKINSON'S DISEASE; REGENERATIVE PROCESS; STROKE; THERAPEUTIC VALUES;

TARGETED DRUG DELIVERY;

DRUG; NANOPARTICLE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN; BRAIN BLOOD VESSEL; CEREBROVASCULAR ACCIDENT; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; HUMAN; NANOENCAPSULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; ANIMAL; DEGENERATIVE DISEASE; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEURODEGENERATIVE DISEASES;

EID: 84974579659     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.05.044     Document Type: Review

References (161)

1. M.J. Cipolla Barriers of the CNS D.N. Granger, J. Granger, Cereb. Circ 2009 Morgan & Claypool Life Sciences San Rafael (CA) (http://www.ncbi.nlm.nih.gov/pubmed/21452434)
2. B. Obermeier, R. Daneman, and R.M. Ransohoff Development, maintenance and disruption of the blood-brain barrier Nat. Med. 19 2013 1584 1596 10.1038/nm.3407
3. D. Mozaffarian, E.J. Benjamin, A.S. Go, D.K. Arnett, M.J. Blaha, M. Cushman, and et al. Heart disease and stroke statistics - 2015 update: a report from the American Heart Association Circulation 131 2015 e29 322 10.1161/cir.0000000000000152
4. 2011 Alzheimer's disease facts and figures Alzheimers Dement. 7 2011 208 244 10.1016/j.jalz.2011.02.004
5. Understanding Parkinson's, Park. Dis. Found. http://www.pdf.org/en/parkinson-statistics 2014 (accessed June 14, 2015)
6. N.J. Abbott, A.A.K. Patabendige, D.E.M. Dolman, S.R. Yusof, and D.J. Begley Structure and function of the blood-brain barrier Neurobiol. Dis. 37 2010 13 25 10.1016/j.nbd.2009.07.030
7. J. Boyer-Di Ponio, F. El-Ayoubi, F. Glacial, K. Ganeshamoorthy, C. Driancourt, M. Godet, and et al. Instruction of circulating endothelial progenitors in vitro towards specialized blood-brain barrier and arterial phenotypes PLoS One 9 2014 e84179 10.1371/journal.pone.0084179
8. J.D. Huber, K.A. Witt, S. Hom, R.D. Egleton, K.S. Mark, and T.P. Davis Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression Am. J. Physiol. Heart Circ. Physiol. 280 2001 H1241 H1248 (http://www.ncbi.nlm.nih.gov/pubmed/11179069)
9. H. Wolburg, and A. Lippoldt Tight junctions of the blood-brain barrier: development, composition and regulation Vasc. Pharmacol. 38 2002 323 337 10.1016/S1537-1891(02)00200-8
10. Y. Persidsky, S.H. Ramirez, J. Haorah, and G.D. Kanmogne Blood-brain barrier: structural components and function under physiologic and pathologic conditions J. NeuroImmune Pharmacol. 1 2006 223 236 10.1007/s11481-006-9025-3
11. Y.K. Choi, and K.-W. Kim Blood-neural barrier: its diversity and coordinated cell-to-cell communication BMB Rep. 41 2008 345 352 10.5483/BMBRep.2008.41.5.345
12. A. Alvarez-Buylla, and J.M. Garcia-Verdugo Neurogenesis in adult subventricular zone J. Neurosci. 22 2002 629 634 (http://www.ncbi.nlm.nih.gov/pubmed/11826091)
13. M. Tavazoie, L. Van der Veken, V. Silva-Vargas, M. Louissaint, L. Colonna, B. Zaidi, and et al. A specialized vascular niche for adult neural stem cells Cell Stem Cell 3 2008 279 288 10.1016/j.stem.2008.07.025
14. M.C. Whitman, W. Fan, L. Rela, D.J. Rodriguez-Gil, and C.A. Greer Blood vessels form a migratory scaffold in the rostral migratory stream J. Comp. Neurol. 516 2009 94 104 10.1002/cne.22093
15. L. Bennett, M. Yang, G. Enikolopov, and L. Iacovitti Circumventricular organs: a novel site of neural stem cells in the adult brain Mol. Cell. Neurosci. 41 2009 337 347 10.1016/j.mcn.2009.04.007
16. A. Hourai, and S. Miyata Neurogenesis in the circumventricular organs of adult mouse brains J. Neurosci. Res. 91 2013 757 770 10.1002/jnr.23206
17. R. Lin, J. Cai, C. Nathan, X. Wei, S. Schleidt, R. Rosenwasser, and et al. Neurogenesis is enhanced by stroke in multiple new stem cell niches along the ventricular system at sites of high BBB permeability Neurobiol. Dis. 74 2015 229 239 10.1016/j.nbd.2014.11.016
18. H. Xin, X. Sha, X. Jiang, L. Chen, K. Law, J. Gu, and et al. The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(e{open}-caprolactone) nanoparticles Biomaterials 33 2012 1673 1681 10.1016/j.biomaterials.2011.11.018
19. J.V. Georgieva, D. Kalicharan, P.O. Couraud, I.A. Romero, B. Weksler, D. Hoekstra, and et al. Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood-brain barrier endothelial cells in vitro Mol. Ther. 19 2011 318 325 10.1038/mt.2010.236
20. R. Gromnicova, H.A. Davies, P. Sreekanthreddy, I.A. Romero, T. Lund, I.M. Roitt, and et al. Glucose-coated gold nanoparticles transfer across human brain endothelium and enter astrocytes in vitro PLoS One 8 2013 e81043 10.1371/journal.pone.0081043
21. X. Gao, J. Qian, S. Zheng, Y. Changyi, J. Zhang, S. Ju, and et al. Overcoming the blood-brain barrier for delivering drugs into the brain by using adenosine receptor nanoagonist ACS Nano 8 2014 3678 3689 10.1021/nn5003375
22. P. Decuzzi, B. Godin, T. Tanaka, S.-Y. Lee, C. Chiappini, X. Liu, and et al. Size and shape effects in the biodistribution of intravascularly injected particles J. Control. Release 141 2010 320 327 10.1016/j.jconrel.2009.10.014
23. S. Aday, R. Cecchelli, D. Hallier-Vanuxeem, M.P. Dehouck, and L. Ferreira Stem cell-based human blood-brain barrier models for drug discovery and delivery Trends Biotechnol. 2016 10.1016/j.tibtech.2016.01.001
24. R. Cecchelli, S. Aday, E. Sevin, C. Almeida, M. Culot, L. Dehouck, and et al. A stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells PLoS One 9 2014 e99733 10.1371/journal.pone.0099733
25. H. Cho, J.H. Seo, K.H.K. Wong, Y. Terasaki, J. Park, K. Bong, and et al. Three-dimensional blood-brain barrier model for in vitro studies of neurovascular pathology Sci. Rep. 5 2015 15222 10.1038/srep15222
26. Q. Liu, J. Hou, X. Chen, G. Liu, D. Zhang, H. Sun, and et al. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models PLoS One 9 2014 e102442 10.1371/journal.pone.0102442
27. C. Freese, S. Reinhardt, G. Hefner, R.E. Unger, C.J. Kirkpatrick, and K. Endres A novel blood-brain barrier co-culture system for drug targeting of Alzheimer's disease: establishment by using acitretin as a model drug PLoS One 9 2014 e91003 10.1371/journal.pone.0091003
28. S. Syvänen, O. Lindhe, M. Palner, B.R. Kornum, O. Rahman, B. Långström, and et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport Drug Metab. Dispos. 37 2009 635 643 10.1124/dmd.108.024745
29. L. Yang, K.K. Shah, and T.J. Abbruscato An in vitro model of ischemic stroke Methods Mol. Biol. 814 2012 451 466 10.1007/978-1-61779-452-0-30
30. A.B. Etame, C.A. Smith, W.C. Chan, and J.T. Rutka Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature Nanomedicine 7 2011 992 1000 10.1016/j.nano.2011.04.004
31. M. Shilo, M. Motiei, P. Hana, and R. Popovtzer Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications Nanoscale 6 2014 2146 2152 10.1039/c3nr04878k
32. S. Guerrero, E. Araya, J.L. Fiedler, J.I. Arias, C. Adura, F. Albericio, and et al. Improving the brain delivery of gold nanoparticles by conjugation with an amphipathic peptide Nanomedicine (Lond.) 5 2010 897 913 10.2217/nnm.10.74
33. A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, S. Wagner, and et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones J. Control. Release 137 2009 78 86 10.1016/j.jconrel.2009.03.002
34. I. Reimold, D. Domke, J. Bender, C.A. Seyfried, H.-E. Radunz, and G. Fricker Delivery of nanoparticles to the brain detected by fluorescence microscopy Eur. J. Pharm. Biopharm. 70 2008 627 632 10.1016/j.ejpb.2008.05.007
35. M. Bramini, D. Ye, A. Hallerbach, M. Nic Raghnaill, A. Salvati, C. Aberg, and et al. Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier ACS Nano 8 2014 4304 4312 10.1021/nn5018523
36. H. Karatas, Y. Aktas, Y. Gursoy-Ozdemir, E. Bodur, M. Yemisci, S. Caban, and et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection J. Neurosci. 29 2009 13761 13769 10.1523/JNEUROSCI.4246-09.2009
37. K. Tsaioun, M. Bottlaender, and A. Mabondzo Alzheimer's Drug Discovery Foundation, ADDME - Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective BMC Neurol. 9 Suppl. 1 2009 S1 10.1186/1471-2377-9-S1-S1
38. W.M. Pardridge Drug targeting to the brain Pharm. Res. 24 2007 1733 1744 10.1007/s11095-007-9324-2
39. M. Goldsmith, L. Abramovitz, and D. Peer Precision nanomedicine in neurodegenerative diseases ACS Nano 8 2014 1958 1965 10.1021/nn501292z
40. T. Patel, J. Zhou, J.M. Piepmeier, and W.M. Saltzman Polymeric nanoparticles for drug delivery to the central nervous system Adv. Drug Deliv. Rev. 64 2012 701 705 10.1016/j.addr.2011.12.006
41. J. Kreuter Drug targeting with nanoparticles Eur. J. Drug Metab. Pharmacokinet. 19 1994 253 256 10.1007/BF03188928
42. J. Kreuter Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv. Drug Deliv. Rev. 71 2014 2 14 10.1016/j.addr.2013.08.008
43. F.A. Cupaioli, F.A. Zucca, D. Boraschi, and L. Zecca Engineered nanoparticles. How brain friendly is this new guest? Prog. Neurobiol. 119-120 2014 20 38 10.1016/j.pneurobio.2014.05.002
44. E. Barbu, E. Molnar, J. Tsibouklis, and D.C. Gorecki The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier Expert Opin. Drug Deliv. 6 2009 553 565 10.1517/17425240902939143
45. P.R. Lockman, R.J. Mumper, M.A. Khan, and D.D. Allen Nanoparticle technology for drug delivery across the blood-brain barrier Drug Dev. Ind. Pharm. 28 2002 1 13 10.1081/DDC-120001481
46. Y. Aktas, M. Yemisci, K. Andrieux, R.N. Gursoy, M.J. Alonso, E. Fernandez-Megia, and et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26 Bioconjug. Chem. 16 2005 1503 1511 10.1021/bc050217o
47. C.H.J. Choi, C.A. Alabi, P. Webster, and M.E. Davis Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles Proc. Natl. Acad. Sci. U. S. A. 107 2010 1235 1240 10.1073/pnas.0914140107
48. D.T. Wiley, P. Webster, A. Gale, and M.E. Davis Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor Proc. Natl. Acad. Sci. U. S. A. 110 2013 8662 8667 10.1073/pnas.1307152110
49. S.D. Kong, J. Lee, S. Ramachandran, B.P. Eliceiri, V.I. Shubayev, R. Lal, and et al. Magnetic targeting of nanoparticles across the intact blood-brain barrier J. Control. Release 164 2012 49 57 10.1016/j.jconrel.2012.09.021
50. M. Yemisci, S. Caban, Y. Gursoy-Ozdemir, S. Lule, R. Novoa-Carballal, R. Riguera, and et al. Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection J. Cereb. Blood Flow Metab. 35 2015 469 475 10.1038/jcbfm.2014.220
51. Q. Song, M. Huang, L. Yao, X. Wang, X. Gu, J. Chen, and et al. Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer's disease by accelerating the clearance of amyloid-beta ACS Nano 8 2014 2345 2359 10.1021/nn4058215
52. R.M. Koffie, C.T. Farrar, L.-J. Saidi, C.M. William, B.T. Hyman, and T.L. Spires-Jones Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging Proc. Natl. Acad. Sci. U. S. A. 108 2011 18837 18842 10.1073/pnas.1111405108
53. C. Zhang, X. Wan, X. Zheng, X. Shao, Q. Liu, Q. Zhang, and et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice Biomaterials 35 2014 456 465 10.1016/j.biomaterials.2013.09.063
54. S. Hanada, K. Fujioka, Y. Inoue, F. Kanaya, Y. Manome, and K. Yamamoto Cell-based in vitro blood-brain barrier model can rapidly evaluate nanoparticles' brain permeability in association with particle size and surface modification Int. J. Mol. Sci. 15 2014 1812 1825 10.3390/ijms15021812
55. G. Sonavane, K. Tomoda, and K. Makino Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size Colloids Surf. B Biointerfaces 66 2008 274 280 10.1016/j.colsurfb.2008.07.004
56. P. Kolhar, A.C. Anselmo, V. Gupta, K. Pant, B. Prabhakarpandian, E. Ruoslahti, and et al. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium Proc. Natl. Acad. Sci. U. S. A. 110 2013 10753 10758 10.1073/pnas.1308345110
57. P.R. Lockman, J.M. Koziara, R.J. Mumper, and D.D. Allen Nanoparticle surface charges alter blood-brain barrier integrity and permeability J. Drug Target. 12 2004 635 641 10.1080/10611860400015936
58. X. Huang, L. Li, T. Liu, N. Hao, H. Liu, D. Chen, and et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo ACS Nano 5 2011 5390 5399 10.1021/nn200365a
59. J. Kreuter, T. Hekmatara, S. Dreis, T. Vogel, S. Gelperina, and K. Langer Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain J. Control. Release 118 2007 54 58 10.1016/j.jconrel.2006.12.012
60. Y. Jallouli, A. Paillard, J. Chang, E. Sevin, and D. Betbeder Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro Int. J. Pharm. 344 2007 103 109 10.1016/j.ijpharm.2007.06.023
61. B. Petri, A. Bootz, A. Khalansky, T. Hekmatara, R. Müller, R. Uhl, and et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants J. Control. Release 117 2007 51 58 10.1016/j.jconrel.2006.10.015
62. K. Ulbrich, T. Hekmatara, E. Herbert, and J. Kreuter Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB) Eur. J. Pharm. Biopharm. 71 2009 251 256 10.1016/j.ejpb.2008.08.021
63. W. Jiang, H. Xie, D. Ghoorah, Y. Shang, H. Shi, F. Liu, and et al. Conjugation of functionalized SPIONs with transferrin for targeting and imaging brain glial tumors in rat model PLoS One 7 2012 e37376 10.1371/journal.pone.0037376
64. K. Ulbrich, T. Knobloch, and J. Kreuter Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB) J. Drug Target. 19 2011 125 132 10.3109/10611861003734001
65. F.J. Martinez-Veracoechea, and D. Frenkel Designing super selectivity in multivalent nano-particle binding Proc. Natl. Acad. Sci. U. S. A. 108 2011 10963 10968 10.1073/pnas.1105351108
66. C.D. Walkey, J.B. Olsen, H. Guo, A. Emili, and W.C. Chan Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake J. Am. Chem. Soc. 134 2012 2139 2147 10.1021/ja2084338
67. N. Doshi, B. Prabhakarpandian, A. Rea-Ramsey, K. Pant, S. Sundaram, and S. Mitragotri Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks J. Control. Release 146 2010 196 200 10.1016/j.jconrel.2010.04.007
68. M. Masserini Nanoparticles for brain drug delivery ISRN Biochem. 2013 2013 238428 10.1155/2013/238428
69. S.D. Li, and L. Huang Nanoparticles evading the reticuloendothelial system: role of the supported bilayer Biochim. Biophys. Acta 1788 2009 2259 2266 10.1016/j.bbamem.2009.06.022
70. S.Y. Lee, M. Ferrari, and P. Decuzzi Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows Nanotechnology 20 2009 495101 10.1088/0957-4484/20/49/495101
71. E.A. Nance, G.F. Woodworth, K.A. Sailor, T.-Y. Shih, Q. Xu, G. Swaminathan, and et al. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue Sci. Transl. Med. 4 2012 149ra119 10.1126/scitranslmed.3003594
72. R.R. Arvizo, O.R. Miranda, D.F. Moyano, C.A. Walden, K. Giri, R. Bhattacharya, and et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles PLoS One 6 2011 e24374 10.1371/journal.pone.0024374
73. R. Khatri, A.M. McKinney, B. Swenson, and V. Janardhan Blood-brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke Neurology 79 2012 10.1212/WNL.0b013e3182697e70
74. H. Lee, and I.S. Pienaar Disruption of the blood-brain barrier in Parkinson's disease: curse or route to a cure? Front. Biosci. (Landmark Ed.) 19 2014 272 280 10.2741/4206
75. B.V. Zlokovic Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders Nat. Rev. Neurosci. 2011 10.1038/nrn3114
76. S. Kyle, and S. Saha Nanotechnology for the detection and therapy of stroke Adv. Healthc. Mater. 3 2014 1703 1720 10.1002/adhm.201400009
77. A. Kumar, Aakriti, and V. Gupta A review on animal models of stroke: an update Brain Res. Bull. 122 2016 35 44 10.1016/j.brainresbull.2016.02.016
78. H. Jiao, Z. Wang, Y. Liu, P. Wang, and Y. Xue Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the blood-brain barrier in a focal cerebral ischemic insult J. Mol. Neurosci. 44 2011 130 139 10.1007/s12031-011-9496-4
79. Y. Yang, E.Y. Estrada, J.F. Thompson, W. Liu, and G.A. Rosenberg Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat J. Cereb. Blood Flow Metab. 27 2007 697 709 10.1038/sj.jcbfm.9600375
80. T. Kulik, Y. Kusano, S. Aronhime, A.L. Sandler, and H.R. Winn Regulation of cerebral vasculature in normal and ischemic brain Neuropharmacology 55 2008 281 288 10.1016/j.neuropharm.2008.04.017
81. S. Warach, and L.L. Latour Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption Stroke 35 2004 2659 2661 10.1161/01.STR.0000144051.32131.09
82. A.-C. Luissint, C. Artus, F. Glacial, K. Ganeshamoorthy, and P.-O. Couraud Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation Fluids Barriers CNS 9 2012 23 10.1186/2045-8118-9-23
83. A.T. Bauer, H.F. Bürgers, T. Rabie, and H.H. Marti Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement J. Cereb. Blood Flow Metab. 30 2009 837 848 10.1038/jcbfm.2009.248
84. Y. Yang, and G.A. Rosenberg Blood-brain barrier breakdown in acute and chronic cerebrovascular disease Stroke 42 2011 3323 3328 10.1161/STROKEAHA.110.608257
85. M. Zhu, D. Xing, Z. Lu, Y. Fan, W. Hou, H. Dong, and et al. DDR1 may play a key role in destruction of the blood-brain barrier after cerebral ischemia-reperfusion Neurosci. Res. 2015 10.1016/j.neures.2015.01.004
86. J. Montaner, C.A. Molina, J. Monasterio, S. Abilleira, J.F. Arenillas, M. Ribó, and et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke Circulation 107 2003 598 603 10.1161/01.CIR.0000046451.38849.90
87. Y. Gu, G. Zheng, M. Xu, Y. Li, X. Chen, W. Zhu, and et al. Caveolin-1 regulates nitric oxide-mediated matrix metalloproteinases activity and blood-brain barrier permeability in focal cerebral ischemia and reperfusion injury J. Neurochem. 120 2012 147 156 10.1111/j.1471-4159.2011.07542.x
88. R. Daneman The blood-brain barrier in health and disease Ann. Neurol. 72 2012 648 672 10.1002/ana.23648
89. A.C.C. da Fonseca, D. Matias, C. Garcia, R. Amaral, L.H. Geraldo, C. Freitas, and et al. The impact of microglial activation on blood-brain barrier in brain diseases Front. Cell. Neurosci. 8 2014 362 10.3389/fncel.2014.00362
90. V. Janardhan, and A.I. Qureshi Mechanisms of ischemic brain injury Curr. Cardiol. Rep. 6 2004 117 123 10.1007/s11886-004-0009-8
91. T. Santos, J. Maia, F. Agasse, S. Xapelli, L. Ferreira, and L. Bernardino Nanomedicine boosts neurogenesis: new strategies for brain repair Integr. Biol. 4 2012 973 981 10.1039/c2ib20129a
92. J.Y. Han, J.Y. Fan, Y. Horie, S. Miura, D.H. Cui, H. Ishii, and et al. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion Pharmacol. Ther. 117 2008 280 295 10.1016/j.pharmthera.2007.09.008
93. C. Tang, H. Xue, C. Bai, R. Fu, and A. Wu The effects of Tanshinone IIA on blood-brain barrier and brain edema after transient middle cerebral artery occlusion in rats Phytomedicine 17 2010 1145 1149 10.1016/j.phymed.2010.03.017
94. X. Chen, Z.W. Zhou, C.C. Xue, X.X. Li, and S.F. Zhou Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier Xenobiotica 37 2007 635 678 10.1080/00498250701411258
95. X. Liu, M. Ye, C. An, L. Pan, and L. Ji The effect of cationic albumin-conjugated PEGylated tanshinone IIA nanoparticles on neuronal signal pathways and neuroprotection in cerebral ischemia Biomaterials 34 2013 6893 6905 10.1016/j.biomaterials.2013.05.021
96. X. Liu, C. An, P. Jin, X. Liu, and L. Wang Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia Biomaterials 34 2013 817 830 10.1016/j.biomaterials.2012.10.017
97. C.V. Gomes, M.P. Kaster, A.R. Tome, P.M. Agostinho, and R.A. Cunha Adenosine receptors and brain diseases: neuroprotection and neurodegeneration Biochim. Biophys. Acta 1808 2011 1380 1399 10.1016/j.bbamem.2010.12.001
98. W.M. Pardridge, T. Yoshikawa, Y.S. Kang, and L.P. Miller Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs J. Pharmacol. Exp. Ther. 268 1994 14 18 (http://www.ncbi.nlm.nih.gov/pubmed/8301550)
99. A.J. Isakovic, N.J. Abbott, and Z.B. Redzic Brain to blood efflux transport of adenosine: blood-brain barrier studies in the rat J. Neurochem. 90 2004 272 286 10.1111/j.1471-4159.2004.02439.x
100. A. Gaudin, M. Yemisci, H. Eroglu, S. Lepetre-Mouelhi, O.F. Turkoglu, B. Donmez-Demir, and et al. Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury Nat. Nanotechnol. 9 2014 1054 1062 10.1038/nnano.2014.274
101. W. Wan, H. Chen, and Y. Li The potential mechanisms of Aβ-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer's disease Int. J. Neurosci. 2013 1 7 10.3109/00207454.2013.825258
102. D. Van Dam, and P.P. De Deyn Animal models in the drug discovery pipeline for Alzheimer's disease Br. J. Pharmacol. 164 2011 1285 1300 10.1111/j.1476-5381.2011.01299.x
103. M.A. Erickson, and W.A. Banks Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease J. Cereb. Blood Flow Metab. 33 2013 1500 1513 10.1038/jcbfm.2013.135
104. T. Kawarabayashi, L.H. Younkin, T.C. Saido, M. Shoji, K.H. Ashe, and S.G. Younkin Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease J. Neurosci. 21 2001 372 381 (http://www.ncbi.nlm.nih.gov/pubmed/11160418)
105. E. Matsubara, J. Ghiso, B. Frangione, M. Amari, Y. Tomidokoro, Y. Ikeda, and et al. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome Ann. Neurol. 45 1999 537 541 10.1002/1531-8249(199904)45:4<537::AID-ANA20>3.0.CO;2-2
106. J. Hardy The amyloid hypothesis for Alzheimer's disease: a critical reappraisal J. Neurochem. 110 2009 1129 1134 10.1111/j.1471-4159.2009.06181.x
107. J.M. Zolezzi, and N.C. Inestrosa Peroxisome proliferator-activated receptors and alzheimer's disease: hitting the blood-brain barrier Mol. Neurobiol. 48 2013 438 451 10.1007/s12035-013-8435-5
108. R. Deane, S.D. Yan, R.K. Submamaryan, B. LaRue, S. Jovanovic, E. Hogg, and et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain Nat. Med. 9 2003 907 913 10.1038/nm890
109. S.-Y. Kook, H. Seok Hong, M. Moon, and I. Mook-Jung Disruption of blood-brain barrier in Alzheimer disease pathogenesis Tissue Barriers 1 2013 e23993 10.4161/tisb.23993
110. H. Du, P. Li, J. Wang, X. Qing, and W. Li The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells Cell. Mol. Neurobiol. 32 2012 141 147 10.1007/s10571-011-9744-8
111. W. Alata, Y. Ye, I. St-Amour, M. Vandal, and F. Calon Human apolipoprotein E E4 expression impairs cerebral vascularization and blood-brain barrier function in mice J. Cereb. Blood Flow Metab. 35 2015 86 94 10.1038/jcbfm.2014.172
112. A. Hafezi-Moghadam, K.L. Thomas, and D.D. Wagner ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage Am. J. Physiol. Cell Physiol. 292 2007 C1256 C1262 10.1152/ajpcell.00563.2005
113. M. Shibata, S. Yamada, S.R. Kumar, M. Calero, J. Bading, B. Frangione, and et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier J. Clin. Invest. 106 2000 1489 1499 10.1172/JCI10498
114. D.M. van Assema, M. Lubberink, P. Rizzu, J.C. van Swieten, R.C. Schuit, J. Eriksson, and et al. Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene EJNMMI Res. 2 2012 57 10.1186/2191-219X-2-57
115. E.E. Tuppo, and H.R. Arias The role of inflammation in Alzheimer's disease Int. J. Biochem. Cell Biol. 37 2005 289 305 10.1016/j.biocel.2004.07.009
116. Y.M. Yang, D.S. Shang, W.D. Zhao, W.G. Fang, and Y.H. Chen Microglial TNF-α-dependent elevation of MHC class I expression on brain endothelium induced by amyloid-beta promotes T cell transendothelial migration Neurochem. Res. 38 2013 2295 2304 10.1007/s11064-013-1138-5
117. C. Iadecola, F. Zhang, K. Niwa, C. Eckman, S.K. Turner, E. Fischer, and et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein Nat. Neurosci. 2 1999 157 161 10.1038/5715
118. A. Ruitenberg, T. den Heijer, S.L.M. Bakker, J.C. van Swieten, P.J. Koudstaal, A. Hofman, and et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study Ann. Neurol. 57 2005 789 794 10.1002/ana.20493
119. E.A. Winkler, Y. Nishida, A.P. Sagare, S.V. Rege, R.D. Bell, D. Perlmutter, and et al. GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration Nat. Neurosci. 18 2015 521 530 10.1038/nn.3966
120. Y. Liu, F. Liu, K. Iqbal, I. Grundke-Iqbal, and C.-X. Gong Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease FEBS Lett. 582 2008 359 364 10.1016/j.febslet.2007.12.035
121. L.J. Blair, H.D. Frauen, B. Zhang, B.A. Nordhues, S. Bijan, Y.-C. Lin, and et al. Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy Acta Neuropathol. Commun. 3 2015 10.1186/s40478-015-0186-2
122. Z. Liu, X. Gao, T. Kang, M. Jiang, D. Miao, G. Gu, and et al. B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide Bioconjug. Chem. 24 2013 997 1007 10.1021/bc400055h
123. K.B. Kurakhmaeva, I.A. Djindjikhashvili, V.E. Petrov, V.U. Balabanyan, T.A. Voronina, S.S. Trofimov, and et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles J. Drug Target. 17 2009 564 574 10.1080/10611860903112842
124. Z.H. Wang, Z.Y. Wang, C.S. Sun, C.Y. Wang, T.Y. Jiang, and S.L. Wang Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain Biomaterials 31 2010 908 915 10.1016/j.biomaterials.2009.09.104
125. J. Xie, S. Lee, and X. Chen Nanoparticle-based theranostic agents Adv. Drug Deliv. Rev. 62 2010 1064 1079 10.1016/j.addr.2010.07.009
126. P.V. Kulkarni, C.A. Roney, P.P. Antich, F.J. Bonte, A.V. Raghu, and T.M. Aminabhavi Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2 2010 35 47 10.1002/wnan.59
127. H.H. Fernandez Updates in the medical management of Parkinson disease Cleve. Clin. J. Med. 79 2012 28 35 10.3949/ccjm.78gr.11005
128. S.A. Jagmag, N. Tripathi, S.D. Shukla, S. Maiti, and S. Khurana Evaluation of models of Parkinson's disease Front. Neurosci. 9 2015 503 10.3389/fnins.2015.00503
129. P. Haussermann, W. Kuhn, H. Przuntek, and T. Muller Integrity of the blood-cerebrospinal fluid barrier in early Parkinson's disease Neurosci. Lett. 300 2001 182 184 10.1016/S0304-3940(01)01574-9
130. R. Kortekaas, K.L. Leenders, J.C.H. Van Oostrom, W. Vaalburg, J. Bart, A.T.M. Willemsen, and et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo Ann. Neurol. 57 2005 176 179 10.1002/ana.20369
131. V. Pisani, A. Stefani, M. Pierantozzi, S. Natoli, P. Stanzione, D. Franciotta, and et al. Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease J. Neuroinflammation 9 2012 188 10.1186/1742-2094-9-188
132. M.T. Gray, and J.M. Woulfe Striatal blood-brain barrier permeability in Parkinson's disease J. Cereb. Blood Flow Metab. 2015 10.1038/jcbfm.2015.32
133. S. Hirano, K. Asanuma, Y. Ma, C. Tang, A. Feigin, V. Dhawan, and et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease J. Neurosci. 28 2008 4201 4209 10.1523/JNEUROSCI.0582-08.2008
134. B.A. Faucheux, A.M. Bonnet, Y. Agid, and E.C. Hirsch Blood vessels change in the mesencephalon of patients with Parkinson's disease Lancet 353 1999 981 982 10.1016/S0140-6736(99)00641-8
135. C. Barcia, V. Bautista, A. Sánchez-Bahillo, E. Fernández-Villalba, B. Faucheux, M. Poza y Poza, and et al. Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian J. Neural Transm. 112 2005 1237 1248 10.1007/s00702-004-0256-2
136. I. Rite, A. Machado, J. Cano, and J.L. Venero Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons J. Neurochem. 101 2007 1567 1582 10.1111/j.1471-4159.2007.04567.x
137. Y.C. Chung, Y.-S. Kim, E. Bok, T.Y. Yune, S. Maeng, and B.K. Jin MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease Mediat. Inflamm. 2013 2013 370526 10.1155/2013/370526
138. B. Desai Bradaric, A. Patel, J.A. Schneider, P.M. Carvey, and B. Hendey Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy J. Neural Transm. 119 2012 59 71 10.1007/s00702-011-0684-8
139. P.L. McGeer, and E.G. McGeer Inflammation and neurodegeneration in Parkinson's disease Parkinsonism Relat. Disord. 10 Suppl. 1 2004 S3 S7 10.1016/j.parkreldis.2004.01.005
140. V. Brochard, B. Combadière, A. Prigent, Y. Laouar, A. Perrin, V. Beray-Berthat, and et al. Infiltration of CD4 + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease J. Clin. Invest. 119 2009 182 192 10.1172/JCI36470
141. R. Cabezas, M. Avila, J. Gonzalez, R.S. El-Bachá, E. Báez, L.M. García-Segura, and et al. Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease Front. Cell. Neurosci. 8 2014 211 10.3389/fncel.2014.00211
142. P.J. Gaillard, A.B.G. de Boer, and D.D. Breimer Pharmacological investigations on lipopolysaccharide-induced permeability changes in the blood-brain barrier in vitro Microvasc. Res. 65 2003 24 31 10.1016/S0026-2862(02)00009-2
143. D. Wong, K. Dorovini-Zis, and S.R. Vincent Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier Exp. Neurol. 190 2004 446 455 10.1016/j.expneurol.2004.08.008
144. A.L. Bartels Blood-brain barrier P-glycoprotein function in neurodegenerative disease Curr. Pharm. Des. 17 2011 2771 2777 10.2174/138161211797440122
145. A. Jangula, and E.J. Murphy Lipopolysaccharide-induced blood brain barrier permeability is enhanced by alpha-synuclein expression Neurosci. Lett. 551 2013 23 27 10.1016/j.neulet.2013.06.058
146. R.A. Yokel Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration J. Alzheimers Dis. 10 2006 223 253 (http://www.ncbi.nlm.nih.gov/pubmed/17119290)
147. B. Leveugle, B.A. Faucheux, C. Bouras, N. Nillesse, G. Spik, E.C. Hirsch, and et al. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases Acta Neuropathol. 91 1996 566 572 10.1007/s004010050468
148. B.A. Faucheux, N. Nillesse, P. Damier, G. Spik, A. Mouatt-Prigent, A. Pierce, and et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease Proc. Natl. Acad. Sci. U. S. A. 92 1995 9603 9607 (http://www.ncbi.nlm.nih.gov/pubmed/7568181)
149. C. Fillebeen, V. Mitchell, D. Dexter, M. Benaissa, J.-C. Beauvillain, G. Spik, and et al. Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment Brain Res. Mol. Brain Res. 72 1999 183 194 10.1016/S0169-328X(99)00221-1
150. P.A. MacDonald, A.A. MacDonald, K.N. Seergobin, R. Tamjeedi, H. Ganjavi, J.-S. Provost, and et al. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI Brain 134 2011 1447 1463 10.1093/brain/awr075
151. R. Pahuja, K. Seth, A. Shukla, R.K. Shukla, P. Bhatnagar, L.K.S. Chauhan, and et al. Trans-blood brain barrier delivery of dopamine loaded nanoparticles reverses functional deficits in parkinsonian rats ACS Nano 2015 10.1021/nn506408v (150331165747002)
152. T. Tarohda, Y. Ishida, K. Kawai, M. Yamamoto, and R. Amano Regional distributions of manganese, iron, copper, and zinc in the brains of 6-hydroxydopamine-induced parkinsonian rats Anal. Bioanal. Chem. 383 2005 224 234 10.1007/s00216-005-3423-x
153. E. Rousseau, P.P. Michel, and E.C. Hirsch The iron-binding protein lactoferrin protects vulnerable dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis Mol. Pharmacol. 84 2013 888 898 10.1124/mol.113.087965
154. J. Lalani, Y. Raichandani, R. Mathur, M. Lalan, K. Chutani, A.K. Mishra, and et al. Comparative receptor based brain delivery of tramadol-loaded poly(lactic-co-glycolic acid) nanoparticles J. Biomed. Nanotechnol. 8 2012 918 927 10.1166/jbn.2012.1462
155. R. Huang, L. Han, J. Li, F. Ren, W. Ke, C. Jiang, and et al. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles J. Gene Med. 11 2009 754 763 10.1002/jgm.1361
156. R. Huang, W. Ke, Y. Liu, D. Wu, L. Feng, C. Jiang, and et al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model J. Neurol. Sci. 290 2010 123 130 10.1016/j.jns.2009.09.032
157. K. Hu, Y. Shi, W. Jiang, J. Han, S. Huang, and X. Jiang Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinsons disease Int. J. Pharm. 415 2011 273 283 10.1016/j.ijpharm.2011.05.062
158. J. Niewoehner, B. Bohrmann, L. Collin, E. Urich, H. Sade, P. Maier, and et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle Neuron 81 2014 49 60 10.1016/j.neuron.2013.10.061
159. Y.J. Yu, Y. Zhang, M. Kenrick, K. Hoyte, W. Luk, Y. Lu, and et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target Sci. Transl. Med. 3 2011 84ra44 10.1126/scitranslmed.3002230
160. Q.-H. Zhou, A. Fu, R.J. Boado, E.K.-W. Hui, J.Z. Lu, and W.M. Pardridge Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain Mol. Pharm. 8 2011 280 285 10.1021/mp1003515
161. W. Li, R. Luo, X. Lin, A.D. Jadhav, Z. Zhang, L. Yan, and et al. Remote modulation of neural activities via near-infrared triggered release of biomolecules Biomaterials 65 2015 76 85 10.1016/j.biomaterials.2015.06.041